Shafique Ahmed, Kashif Zafar, Esha Mukarram, Umair Asghar, Shazia Anwar.
Comparing Safety Profile Of Rosuvastatin With Simvastatin In Terms Of Muscle Symptoms.
J Cardiovascular Dis Jan ;14(2):38-41.

OBJECTIVES: To compare frequency of muscle symptoms among patients taking either simvastatin or rosuvastatin. METHODS: Patients who were taking either simvastatin or rosuvastatin for at least past 2 months were enrolled in the study. They were divided into two groups: group A and group B receiving Simvastatin and Rosuvastatin respectively. Detailed clinical history was taken in each case. Blood samples were drawn from all the patients for serum LDL cholesterol, triglycerides, creatinine and creatine kinase levels. Primary outcome variables included myalgia, myopathy and rhabdomyolysis. RESULTS: The two groups were comparable in terms of various baseline characteristics such as mean age (54.12±9.67 vs 55.20±10.11), gender (20/30 vs 15/35), mean BMI (28.46±4.12 vs 29.04±3.87), serum LDL cholesterol (176.60±58.13 vs 183.63±64.37) and serum triglycerides level (198.61±83.31 vs 203.45±88.12). Myalgia was reported in 10(20%) patients in group A whereas 15(30%) patients reported myalgia in group B. CONCLUSION: Rosuvastatin was equally safe as simvastatin with respect to various musculoskeletal side effects.

PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com